BioCentury | Jan 16, 2021
Politics, Policy & Law

Woodcock’s appointment as acting FDA commissioner could be audition for permanent position

Politics, Policy & Law When Janet Woodcock moves into the FDA commissioner’s office next week, she will take charge, at least on an acting basis, of an agency that has been pummeled for months. President...
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

Paige’s $100 million series C suggests investor enthusiasm for cancer diagnostics extends beyond liquid biopsy and includes machine-learning tools for image-based pathology.  The New York-based company will use the funds to speed development of clinical applications,...
BioCentury | Jan 13, 2021
Politics, Policy & Law

Woodcock to serve as acting FDA commissioner, Sharfstein a contender for top FDA job

David Kessler is out of the running for nomination as FDA commissioner, leaving Joshua Sharfstein as a front-runner to lead FDA, sources briefed by the Biden transition team told BioCentury. While the list of candidates...
BioCentury | Jan 13, 2021
Politics, Policy & Law

BIO, PhRMA ‘pause’ political giving

In the wake of the storming of the U.S. Capitol, BIO and PhRMA have joined other trade associations and U.S. companies in reassessing their criteria for making political contributions. The biopharma trade associations have not...
BioCentury | Jan 12, 2021
Regulation

HHS imposes new review timeline report policy on FDA

HHS Monday announced that it will require FDA to collect and report data about the length of new drug reviews using metrics that are different, and far more stringent, than those the agency has traditionally...
BioCentury | Jan 11, 2021
Politics, Policy & Law

The U.S. needs a COVID commission: Editor’s Commentary

No country was better prepared for a pandemic than the United States and in no country has the response been as disastrously incompetent. The American public needs to know why. By the end of January,...
BioCentury | Jan 11, 2021
Politics, Policy & Law

Truth and facts matter. Say it out loud: Editor’s Commentary

First they came for the climate scientists, and I did not speak out because I wasn’t a climate scientist. Then they came for the mask-wearers, and I did not speak out because I was...
BioCentury | Jan 9, 2021
Tools & Techniques

What DeepMind’s leap means for structure-based drug developers

The step change in protein folding prediction pioneered by Alphabet’s DeepMind stands to widen the funnel of targets tackled with structure-based platforms, including newly discovered proteins from...
BioCentury | Jan 5, 2021
Product Development

Crucible of COVID, ahoy 2021 & cancer deal trends: a BioCentury podcast

The New Year kicks off with the new — a new U.S. president readying to enter the White House with a new take on drug pricing, and investors eyeing new modalities — and too much of the...
BioCentury | Jan 1, 2021
Product Development

Not done yet. The COVID R&D Alliance has plenty on its plate for 2021

With little fuss or fanfare, the COVID R&D Alliance was created early in the pandemic by the biopharma industry’s biggest players to solve one of the world’s most devastating problems in a century....
Items per page:
1 - 10 of 2429
BioCentury | Jan 16, 2021
Politics, Policy & Law

Woodcock’s appointment as acting FDA commissioner could be audition for permanent position

Politics, Policy & Law When Janet Woodcock moves into the FDA commissioner’s office next week, she will take charge, at least on an acting basis, of an agency that has been pummeled for months. President...
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

Paige’s $100 million series C suggests investor enthusiasm for cancer diagnostics extends beyond liquid biopsy and includes machine-learning tools for image-based pathology.  The New York-based company will use the funds to speed development of clinical applications,...
BioCentury | Jan 13, 2021
Politics, Policy & Law

Woodcock to serve as acting FDA commissioner, Sharfstein a contender for top FDA job

David Kessler is out of the running for nomination as FDA commissioner, leaving Joshua Sharfstein as a front-runner to lead FDA, sources briefed by the Biden transition team told BioCentury. While the list of candidates...
BioCentury | Jan 13, 2021
Politics, Policy & Law

BIO, PhRMA ‘pause’ political giving

In the wake of the storming of the U.S. Capitol, BIO and PhRMA have joined other trade associations and U.S. companies in reassessing their criteria for making political contributions. The biopharma trade associations have not...
BioCentury | Jan 12, 2021
Regulation

HHS imposes new review timeline report policy on FDA

HHS Monday announced that it will require FDA to collect and report data about the length of new drug reviews using metrics that are different, and far more stringent, than those the agency has traditionally...
BioCentury | Jan 11, 2021
Politics, Policy & Law

The U.S. needs a COVID commission: Editor’s Commentary

No country was better prepared for a pandemic than the United States and in no country has the response been as disastrously incompetent. The American public needs to know why. By the end of January,...
BioCentury | Jan 11, 2021
Politics, Policy & Law

Truth and facts matter. Say it out loud: Editor’s Commentary

First they came for the climate scientists, and I did not speak out because I wasn’t a climate scientist. Then they came for the mask-wearers, and I did not speak out because I was...
BioCentury | Jan 9, 2021
Tools & Techniques

What DeepMind’s leap means for structure-based drug developers

The step change in protein folding prediction pioneered by Alphabet’s DeepMind stands to widen the funnel of targets tackled with structure-based platforms, including newly discovered proteins from...
BioCentury | Jan 5, 2021
Product Development

Crucible of COVID, ahoy 2021 & cancer deal trends: a BioCentury podcast

The New Year kicks off with the new — a new U.S. president readying to enter the White House with a new take on drug pricing, and investors eyeing new modalities — and too much of the...
BioCentury | Jan 1, 2021
Product Development

Not done yet. The COVID R&D Alliance has plenty on its plate for 2021

With little fuss or fanfare, the COVID R&D Alliance was created early in the pandemic by the biopharma industry’s biggest players to solve one of the world’s most devastating problems in a century....
Items per page:
1 - 10 of 2429